PTGS2 and Parkinson disease: Treatment of PYC attenuated the expression of NF-κB, IL-1β, TNF-α, cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), contributing to its neuroprotective effect in a 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine (MPTP)-induced Parkinson’s disease (PD) model [71].